Last reviewed · How we verify
Anti R-IL2 + Cyclosporine then Everolimus
Anti R-IL2 + Cyclosporine then Everolimus is a Immunosuppressive combination therapy Small molecule drug developed by University Hospital, Brest. It is currently in Phase 3 development for Allograft rejection prevention in organ transplantation.
This combination therapy sequentially suppresses T-cell activation via anti-IL-2 receptor blockade and calcineurin inhibition, followed by mTOR inhibition to prevent allograft rejection.
This combination therapy sequentially suppresses T-cell activation via anti-IL-2 receptor blockade and calcineurin inhibition, followed by mTOR inhibition to prevent allograft rejection. Used for Allograft rejection prevention in organ transplantation.
At a glance
| Generic name | Anti R-IL2 + Cyclosporine then Everolimus |
|---|---|
| Sponsor | University Hospital, Brest |
| Drug class | Immunosuppressive combination therapy |
| Target | IL-2 receptor, calcineurin, mTOR |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | Phase 3 |
Mechanism of action
Anti-R-IL2 (anti-IL-2 receptor) monoclonal antibodies block IL-2 signaling on T cells, reducing their proliferation. Cyclosporine inhibits calcineurin-dependent T-cell activation. Everolimus, an mTOR inhibitor, further suppresses T-cell and B-cell proliferation. This sequential approach targets multiple checkpoints in the immune response to prevent organ transplant rejection.
Approved indications
- Allograft rejection prevention in organ transplantation
Common side effects
- Infection (bacterial, viral, fungal)
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Hyperlipidemia
- Bone marrow suppression
Key clinical trials
- EVEROLD LONG TERM FOLLOW-UP
- mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti R-IL2 + Cyclosporine then Everolimus CI brief — competitive landscape report
- Anti R-IL2 + Cyclosporine then Everolimus updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI
Frequently asked questions about Anti R-IL2 + Cyclosporine then Everolimus
What is Anti R-IL2 + Cyclosporine then Everolimus?
How does Anti R-IL2 + Cyclosporine then Everolimus work?
What is Anti R-IL2 + Cyclosporine then Everolimus used for?
Who makes Anti R-IL2 + Cyclosporine then Everolimus?
What drug class is Anti R-IL2 + Cyclosporine then Everolimus in?
What development phase is Anti R-IL2 + Cyclosporine then Everolimus in?
What are the side effects of Anti R-IL2 + Cyclosporine then Everolimus?
What does Anti R-IL2 + Cyclosporine then Everolimus target?
Related
- Drug class: All Immunosuppressive combination therapy drugs
- Target: All drugs targeting IL-2 receptor, calcineurin, mTOR
- Manufacturer: University Hospital, Brest — full pipeline
- Therapeutic area: All drugs in Immunology / Transplantation
- Indication: Drugs for Allograft rejection prevention in organ transplantation
- Compare: Anti R-IL2 + Cyclosporine then Everolimus vs similar drugs
- Pricing: Anti R-IL2 + Cyclosporine then Everolimus cost, discount & access